NCT01856179

Brief Summary

The objective of this study is to investigate the conversion of the precursors ALA and SDA into n-3 LC-PUFA (EPA, DPA and DHA) in humans by oral supplementation of Echium oil in comparison with SDA soybean oil (positive control). In addition, the accumulation of n-3 LC-PUFA is compared between subpopulations of different age, gender and physiological conditions (overweight, increased serum total cholesterol).

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
78

participants targeted

Target at P75+ for early_phase_1

Timeline
Completed

Started Mar 2011

Shorter than P25 for early_phase_1

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2011

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2011

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

November 29, 2011

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2012

Completed
1.1 years until next milestone

First Posted

Study publicly available on registry

May 17, 2013

Completed
Last Updated

May 17, 2013

Status Verified

May 1, 2013

Enrollment Period

5 months

First QC Date

November 29, 2011

Last Update Submit

May 14, 2013

Conditions

Keywords

Conversion of ALA and SDAMetabolism of n-3 fatty acids

Outcome Measures

Primary Outcomes (1)

  • eicosapentaenic acid

    eicosapentaenic acid in lipids of plasma, erythrocytes and peripheral mononuclear cells (% of total identified fatty acid methyl esters)

    after 0,7, 56 days

Secondary Outcomes (1)

  • Lipid mediators derived from AA, EPA and DGLA such as HETE species (5-HETE; 8-HETE, etc.)

    0 and 56 days

Study Arms (3)

Echium oil young

EXPERIMENTAL

BMI\<25, age 20-30

Dietary Supplement: Echium oil

Echium oil older

EXPERIMENTAL

age 40-70 BMI \<25

Dietary Supplement: Echium oil

Echium oil older, overweight

EXPERIMENTAL

age 40-70 BMI \>25

Dietary Supplement: Echium oil

Interventions

Echium oilDIETARY_SUPPLEMENT

Oil of Echium platagineum (natural plant oil) ca. 15-18 g/d (Croda)

Echium oil olderEchium oil older, overweightEchium oil young

Eligibility Criteria

Age20 Years - 70 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • healthy subjects

You may not qualify if:

  • cholesterol lowering drugs
  • chronic diseases
  • pregnancy, lactation
  • intake of nutritional supplements

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Friedrich Schiller University of Jena

Jena, Thuringia, 07743, Germany

Location

Related Publications (2)

  • Kuhnt K, Weiss S, Kiehntopf M, Jahreis G. Consumption of echium oil increases EPA and DPA in blood fractions more efficiently compared to linseed oil in humans. Lipids Health Dis. 2016 Feb 18;15:32. doi: 10.1186/s12944-016-0199-2.

  • Kuhnt K, Fuhrmann C, Kohler M, Kiehntopf M, Jahreis G. Dietary echium oil increases long-chain n-3 PUFAs, including docosapentaenoic acid, in blood fractions and alters biochemical markers for cardiovascular disease independently of age, sex, and metabolic syndrome. J Nutr. 2014 Apr;144(4):447-60. doi: 10.3945/jn.113.180802. Epub 2014 Feb 19.

MeSH Terms

Conditions

HypercholesterolemiaOverweight

Condition Hierarchy (Ancestors)

HyperlipidemiasDyslipidemiasLipid Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesOvernutritionNutrition DisordersBody WeightSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • Katrin Kuhnt, Dr. rer. nat

    University of Jena, Insitute of Nutrition

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
early phase 1
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Prof. Dr. habil.

Study Record Dates

First Submitted

November 29, 2011

First Posted

May 17, 2013

Study Start

March 1, 2011

Primary Completion

August 1, 2011

Study Completion

April 1, 2012

Last Updated

May 17, 2013

Record last verified: 2013-05

Locations